NCT00006098View on ClinicalTrials.gov

PS-341 in Treating Patients With Hematologic Cancer

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

April 30, 2000

Primary Completion Date

October 31, 2001

Study Completion Date

October 31, 2001

Conditions
LeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic Syndromes
Interventions
DRUG

bortezomib

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00006098 - PS-341 in Treating Patients With Hematologic Cancer | Biotech Hunter | Biotech Hunter